Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What CAPLIPOINT guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 15 May 2025 | Board outcome for the year ended March 31, 2025: interim dividend of INR 3.00 per equity share (150%) on face value INR 2, with May 30, 2025 fixed as record date. Audited standalone and consolidated FY25 results approved: consolidated total revenue INR 2,033.9 crore (up 15.5% YoY), PAT INR 541.1 crore (up 17.3%),... NSE copy | +23.3 % | +11.2 % | +2.6 % |
Filings tagged as guidance, newest first (1 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 12 Aug 2026 | Management change | Caplin Point Laboratories' board on August 12, 2026 approved unaudited Q1 FY27 results (quarter ended June 30, 2026): consolidated total revenue Rs 643.9 crore (up 20.7% YoY), consolidated PAT Rs 179.1 crore (up 18.8% YoY), consolidated basic EPS Rs 23.27. Board recommended a final dividend of Rs 4 per equity share... NSE copy |
| 12 Aug 2026 | Management change | Board meeting outcome dated August 12, 2026: unaudited standalone and consolidated results for the quarter ended June 30, 2026 approved; standalone revenue from operations Rs 202.95 crore and net profit Rs 120.38 crore for the quarter; consolidated revenue from operations Rs 610.36 crore and net profit Rs 179.09... NSE copy |
| 12 Aug 2026 | Management change | Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2026, with a press release and investor presentation enclosed. Standalone: revenue from operations Rs 202.95 crore (Q1 FY27) vs Rs 182.57 crore a year earlier; net profit Rs 120.38 crore vs Rs 85.89 crore; basic EPS Rs 15.84... NSE copy |
| 05 Nov 2025 | Management change | Caplin Point Laboratories filed the outcome of its board meeting held on 5 November 2025, which approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2025. Standalone revenue from operations was Rs 175.18 crores for the quarter and Rs 357.75 crores for the half... NSE copy |
| 15 May 2025 | Legal or regulatory | Board outcome for the year ended March 31, 2025: interim dividend of INR 3.00 per equity share (150%) on face value INR 2, with May 30, 2025 fixed as record date. Audited standalone and consolidated FY25 results approved: consolidated total revenue INR 2,033.9 crore (up 15.5% YoY), PAT INR 541.1 crore (up 17.3%),... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (5 in all). A list of what was filed, not a judgement of the company.